Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction

International Journal of Biological Sciences

Volumn 8, Issue 6, 2012, Pages 811-818

  Long, Guangwen ^a   Wang, Feng ^a   Duan, Quanlu ^a   Chen, Fuqiong ^a   Yang, Shenglan ^a   Gong, Wei ^a   Wang, Yan ^a   Chen, Chen ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AMI; Biomarker; Circulating miRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MIRN1 MICRORNA, HUMAN; MIRN126 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOCARDIAL INFARCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84863763858     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4439     Document Type: Article

References (41)

1. Montgomery RL, van Rooij E. Therapeutic advances in MicroRNA targeting. J Cardiovasc Pharmacol. 2011; 57: 1-7.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-66.
3. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007; 101: 1225-36.
4. Wu W. MicroRNA: potential targets for the development of novel drugs? Drugs R D. 2010; 10: 1-8.
5. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, et al. An analysis of human microRNA and disease associations. PLoS One. 2008; 3: e3420.
6. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010; 391: 73-7.
7. Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res. 2009; 84: 434-41.
8. Pan ZW, Lu YJ, Yang BF. MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta Pharmacol Sin. 2010; 31: 1-9.
9. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, et al. MicroRNA-1 and-133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One. 2011; 6: e28324.
10. Cioffi JA, Yue WY, Mendolia-Loffredo S, Hansen KR, Wackym PA, Hansen MR. MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otol Neurotol. 2010; 31: 1455-62.
11. Rigoutsos I, Furnari F. Gene-expression forum: Decoy for microRNAs. Nature. 2010; 465: 1016-7.
12. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature. 2010; 464: 1196-200.
13. Huang MB, Xu H, Xie SJ, Zhou H, Qu LH. Insulin-like growth factor-1 receptor is regulated by microRNA-133 during skeletal myogenesis. PLoS One. 2011; 6: e29173.
14. Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci. 2008; 9: 978-99.
15. Rossbach M. Small non-coding RNAs as novel therapeutics. Curr Mol Med. 2010; 10: 361-8.
16. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010; 115: 163-9.
17. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010; 31: 2765-73.
18. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010; 467: 986-90.
19. Rouget C, Papin C, Boureux A, Meunier AC, Franco B, Robine N, et al. Maternal mRNA deadenylation and decay by the piRNA pathway in the early Drosophila embryo. Nature. 2010; 467: 1128-32.
20. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011; 6: e28486.
21. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011; 31: 2383-90.
22. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; 115: e356-75.
23. Yasui N, Kajimoto K, Sumiya T, Okuda T, Iwai N. The monocyte chemotactic protein-1 gene may contribute to hypertension in Dahl salt-sensitive rats. Hypertens Res. 2007; 30: 185-93.
24. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012; 14: 147-54.
25. Ramachandran V, Chen X. Degradation of microRNAs by a family of exoribonucleases in Arabidopsis. Science. 2008; 321: 1490-2.
26. Shi B, Guo Y, Wang J, Gao W. Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc Disord. 2010; 10: 11.
27. Small EM, Sutherland LB, Rajagopalan KN, Wang S, Olson EN. MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circ Res. 2010; 107: 1336-44.
28. Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010; 122: 1308-18.
29. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980-4.
30. Moazed D. Small RNAs in transcriptional gene silencing and genome defence. Nature. 2009; 457: 413-20.
31. Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther. 2010; 125: 92-104.
32. Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training: molecular mechanisms. Circulation. 2010; 122: 1221-38.
33. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010; 122: 2378-87.
34. Abdellatif M. MicroRNA: redefining mechanisms in cardiovascular diseases. J Cardiovasc Pharmacol. 2010; 56: 441-3.
35. Bauersachs J. Regulation of myocardial fibrosis by MicroRNAs. J Cardiovasc Pharmacol. 2010; 56: 454-9.
36. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 2009; 55: 1944-9.
37. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009; 27: 255-68.
38. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007; 13: 486-91.
39. Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang Y, et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol. 2009; 158: 1227-35.
40. Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007; 315: 1278-82.
41. Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 2010; 1806: 200-7.